Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Merck & Co. is starting construction on a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

Some four years into its run as an independent women’s health outfit, Organon is parting ways with its first CEO after an ...

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...

Sales of the drug, which comprised nearly half of Merck’s sales last year, totaling $29.5 billion, are expected to peak ...

Merck's $70 billion US investment plan includes a $3 billion facility in Virginia, creating 500 jobs and enhancing ...

Merck (MRK) delivered annual earnings growth of 19.4%, outpacing its own 5-year average growth rate of 13.4%. Profit margins ...

Merck Foundation Chief Executive Officer (CEO) meets Senegal First Lady & 13 First Ladies of Africa at 7th Edition of Merck Foundation First Ladies Initiative Summit to discuss the strategy to build h ...